Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North ...

A review of the film in Variety notes, “Patricia Clarkson can be larger-than-life… but the beauty of her performance in Lilly ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...